[Treatment of Raynaud's phenomenon].
Levy
Y
Y
Shoenfeld
Y
Y
D000317:Adrenergic alpha-Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use; D045930:Anabolic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D011453:Prostaglandins / Q000493:pharmacokinetics / Q000627:therapeutic use; D011928:Raynaud Disease / Q000188:drug therapy* / Q000628:therapy; D014665:Vasodilator Agents / Q000493:pharmacokinetics / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D045930:Anabolic Agents; D011453:Prostaglandins; D014665:Vasodilator Agents